In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c
- PMID: 31525763
- DOI: 10.7326/ACPJ201909170-029
In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c
Comment on
-
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.Lancet. 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. Lancet. 2019. PMID: 31186120 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical